Moleculin Biotech, (NASDAQ:MBRX) stock observed trading -81.92% off 52-week high price. On the other end, the stock has been noted 76.28% away from low price over the last 52-weeks. The stock disclosed a move of -19.49% away from 50 day moving average and -42.71% away from 200 day moving average. Moving closer, we can see that shares have been trading 0.08% off 20-day moving average. It has market cap of $29.87M.

On April 2, 2020, Moleculin Biotech, (NASDAQ:MBRX) a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, disclosed it has completed the latest (210 mg/m2) cohort in its European open label, single arm Phase 1/2 clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML).  A total of 19 patients have been treated in the US and Europe, and all results continue to show Annamycin to be safe, and, especially, all have shown Annamycin to be free of cardiotoxicity.  Of those, 10 have been treated at or above the FDA lifetime maximum anthracycline exposure.

The Phase 1 portion of this clinical trial, which is described in more detail later in this press release, is designed to establish the safety of Annamycin and to determine the Recommended Phase 2 Dose to be used in the Phase 2 portion of the trial.  While the Primary Endpoint of the Phase 1 portion is safety, a Secondary Endpoint is the assessment of efficacy generally defined as an improvement in bone marrow biopsy results sufficient to qualify patients for a potentially curative bone marrow transplant.  The Company cautions not to place undue reliance on interim results.

The USA based company Moleculin Biotech moved with change of -1.06% to $0.57 with the total traded volume of 615396 shares in recent session versus to an average volume of 1.42M. The stock was observed in the 5 days activity at -8.16%. The one month performance of stock was -18.66%. MBRX’s shares are at -38.13% for the quarter and driving a -38.10% return over the course of the past year and is now at -37.78% since this point in 2018.  Right now the stock beta is 1.65. The average volatility for the week and month was at 10.91% and 21.92% respectively. There are 52.46M shares outstanding and 46.32M shares are floated in market.